US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

OraSure Technologies, Inc. - Common Stock (NQ:OSUR)

3.900 +0.100 (+2.63%)
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about OraSure Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
OraSure (OSUR) Q2 2026 Earnings Call Transcript ↗
Revenue beat guidance at $30.6M, but IntelliQ CT/NG FDA clearance delayed to 2027. 
Via The Motley Fool
Topics Earnings
News headline image
OraSure Technologies Q2 Earnings Call Highlights ↗
OraSure Technologies (NASDAQ:OSUR) reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth... 
Via MarketBeat
Topics Earnings
OraSure Technologies (NASDAQ:OSUR) Q2 Beat Tempered by Soft Q3 Guidance ↗
Via Chartmill
News headline image
OraSure Announces Second Quarter 2026 Financial Results
From OraSure Technologies, Inc.
Via GlobeNewswire
OraSure Technologies (NASDAQ:OSUR) Q1 2026 Results Meet Revenue Forecast but Losses Widen, Shares Dip ↗
Via Chartmill
OraSure Technologies Inc (NASDAQ:OSUR) Reports Mixed Q4 2025 Results Amid Strategic Transition ↗
Via Chartmill
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Receives Emergency Use Authorization for Second Generation Ebola Test
The rapid test detects the Bundibugyo virus associated with the current outbreak and can support the diagnosis of both symptomatic individuals and deceased patients. 
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections
The clearance combines OraSure’s Colli-Pee™•Dx Urine Collection Kit for at-home sample collection with Roche’s cobas® molecular lab testing equipment 
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
Is Co-Diagnostics National Security’s Next Diagnostic Pick? ↗
Via MarketBeat
News headline image
OraSure (OSUR) Q1 2026 Earnings Transcript ↗
OraSure (OSUR) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
OraSure Announces First Quarter 2026 Financial Results
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Technologies Appoints John D. Bertrand to its Board of Directors
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Highlights Significant Operational Progress and Value Creation Initiatives Following Letter from Altai Capital
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
Altai Capital Management Issues Letter to OraSure Board Outlining Five-Pillar Case for Change in Response to Significant and Continued Underperformance
From Altai Capital Management, L.P.
Via Business Wire
News headline image
OraSure Announces Fourth Quarter 2025 Financial Results
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure to Launch OraQuick™ HIV Self-Test in Canada
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure to Announce Fourth Quarter 2025 Financial Results and Host Earnings Call on February 25th
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
No Shareholder Action Required at This Time 
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
Altai Capital Management Nominates Two Highly-Qualified Candidates for Election to OraSure Board of Directors
From Altai Capital Management, L.P.
Via Business Wire
News headline image
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Technologies Issues Statement Regarding Altai Capital’s Intent to Nominate Director Candidates
No Shareholder Action Required at This Time 
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
Altai Capital Management Announces Intention to Nominate Two Highly-Qualified Candidates for Election to OraSure Board of Directors
From Altai Capital Management, L.P.
Via Business Wire
News headline image
OraSure to Participate in Upcoming Investor Conference
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure (OSUR) Q3 2025 Earnings Call Transcript ↗
OraSure (OSUR) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
OraSure Announces Third Quarter 2025 Financial Results
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure to Announce Third Quarter 2025 Financial Results and Host Earnings Call on November 5th
From OraSure Technologies, Inc.
Via GlobeNewswire
News headline image
OraSure Technologies Appoints Steven K. Boyd to its Board of Directors
From OraSure Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >